Do Tyrosine Kinase Inhibitors Lose Favor in Treatment of First-Line Metastatic Renal Cell Carcinoma?

Future Oncology - United Kingdom
doi 10.2217/fon-2018-0503
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Future Medicine Ltd

Related search

Brain Metastases From Renal Cell Carcinoma in the Era of Tyrosine Kinase Inhibitors

Clinical Genitourinary Cancer
OncologyUrology
2013English

Survival Benefits of Second-Line Axitinib Versus Everolimus After First Line Sunitinib Treatment in Metastatic Renal Cell Carcinoma

Pathology and Oncology Research
MedicineForensic MedicinePathologyOncologyCancer Research
2020English

Economic Evaluation of First Line Treatment for Advanced Non Small Cell Lung Cancer Using Tyrosine Kinase Inhibitors in Malaysia

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2016English

Concomitant Oral Tyrosine Kinase Inhibitors and Bisphosphonates in Advanced Renal Cell Carcinoma With Bone Metastases

British Journal of Cancer
Cancer ResearchOncology
2012English

Angiotensin Inhibitors as Treatment of Sunitinib/Pazopanib-Induced Hypertension in Metastatic Renal Cell Carcinoma

Clinical Genitourinary Cancer
OncologyUrology
2017English

Pcn190 - Cost-Effectiveness of Nivolumab + Ipilimumab in First-Line Treatment of Advanced or Metastatic Renal Cell Carcinoma in the Netherlands

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

A Population-Based Study Examining the Effect of Tyrosine Kinase Inhibitors on Survival in Metastatic Renal Cell Carcinoma in Alberta and the Role of Nephrectomy Prior to Treatment

Canadian Urological Association Journal
Urology
2013English

Sunitinib in the Treatment of Metastatic Renal Cell Carcinoma

Therapeutic Advances in Urology
Urology
2016English

Anlotinib Versus Sunitinib as First‐Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial

Oncologist
Cancer ResearchMedicineOncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy